Featured News

Featured Story

Dr. Robin Orozco, CBID Research Project Leader

Dr. Robin Orozco is an Assistant Professor at the University of Kansas, where her lab studies how specific allelic variants affect immune responses. She talks about what we can learn from mouse models and the role of PTPN22 in antiviral immunity. (36:48)...

Orozco podcast ep116

More News

Mon, 12/15/2025

Dr. Michael Wang, CBID Pilot Project investigator, speaks about the Lab2Market Accelerator

Inside a lab, innovation can feel both exciting and uncertain. But for KU researchers, discovery may only be the beginning. Turning ideas into companies that create jobs, technologies, and growth in Kansas takes more than data—it takes courage, guidance, and a community that believes in what’s possible.
Mon, 11/24/2025

Orozco lab overturns the idea that a “risk gene” carried by millions of people influences production of Type 1 interferon in the immune system.

A new paper from the University of Kansas overturns the idea that a “risk gene” carried by millions of people worldwide influences production of Type 1 interferon, a workhorse of the immune system. ...

Tue, 11/11/2025

Fehr research shows human gene PARP14 could be novel target for viral diseases or immune-mediated disorders

Researchers at the University of Kansas have discovered a human gene, the protein PARP14, plays a role in regulating interferon, part of the body’s innate immune system. Their study, appearing in journal mBio, could guide development of antiviral therapies for several groups of viral infection. ...

Tue, 10/07/2025

Dr. Robin Orozco, CBID Research Project Leader

Dr. Robin Orozco is an Assistant Professor at the University of Kansas, where her lab studies how specific allelic variants affect immune responses. She talks about what we can learn from mouse models and the role of PTPN22 in antiviral immunity. (36:48)...

Wed, 09/17/2025

Boskovic earns NSF grant to support new research for pharmaceutical drug discoveries

Zarko Boskovic, assistant professor of medicinal chemistry in the KU School of Pharmacy, has been awarded a $575,000 grant from the National Science Foundation. The grant will be used in the Boskovic Lab to shed light on the process of efficiently and selectively creating new molecules that hold potential for drug discovery.
See all news